CSN Login
Members Online: 17

You are here

NRG Oncology trial sets new standard regimen for women with uterine carcinosarcomas (MMMT)

cmb's picture
cmb
Posts: 298
Joined: Jan 2018

Results from the phase III NRG Oncology clinical trial GOG 0261 comparing paclitaxel plus carboplatin (PC) to paclitaxel plus ifosfamide (PI) in women with stage I-IV, recurrent carcinosarcoma of the uterus or ovary, indicate that the PC combination treatment should be considered a standard of care for this patient population.

You can read the full summary at:

https://www.eurekalert.org/pub_releases/2019-06/no-not_1053119.php

janaes
Posts: 712
Joined: May 2016

Thats interesting. Thanks cmb

Armywife's picture
Armywife
Posts: 211
Joined: Feb 2018

CMB, thanks so much for all you do for this board!

cmb's picture
cmb
Posts: 298
Joined: Jan 2018

Thank you for the kind words, Armywife. This site has such a wonderful collection of women who share their experiences that I'm happy that I can contribute in a small way.

Subscribe to Comments for "NRG Oncology trial sets new standard regimen for women with uterine carcinosarcomas (MMMT)"